n°179

February 2017

Issue Contents
Editorial

Free  Neuroleptics: too readily prescribed

p.31

Marketing Authorisations

Sacubitril + valsartan (Entresto°) in chronic heart failure

p.33-37
Favourable results in highly selected patients

Mepolizumab (Nucala°) in asthma

p.38-39
Another poorly effective immunosuppressant

Perampanel (Fycompa°) and refractory generalised epilepsy

p.40-41
A last resort

Free  Idebenone (Raxone°) and Leber hereditary optic neuropathy

p.41
Unacceptable risks, in the absence of proven efficacy

Regulators' failings

p.41

Entecavir (Baraclude°) and chronic hepatitis B in children

p.42-43
Another option, but many long-term unknowns

INN Common stem: -peridone

p.43

Adverse Effects

Extrapyramidal disorders with domperidone

p.44

Tramadol: fatal overdoses in children

p.44-45

Hormonal contraceptive + enzyme inducer: unintended pregnancies

p.45

Long-acting injectable olanzapine: post-injection syndrome

p.46

Methylphenidate: cardiac disorders

p.46-47

Free  Benfluorex: adverse effects reviewed, 1976-2015

p.47

NSAIDs in children: gastrointestinal bleeding

p.47

Reviews

Mosquito and tick bites: individual prophylaxis

p.48-50
First-choice treatments

Metastatic colorectal cancer

p.51
Regorafenib: a few extra weeks of life, but with many serious adverse effects

Outlook

The French "transparency" database: what are the "agreements" between Prescrire and drug companies?

p.52-54
Drug companies pay for subscriptions to Prescrire

Switzerland: community pharmacists providing consultations for common medical conditions

p.54-55
Initial evaluations are positive

Masthead

Free  Masthead

p.30

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe